BioHarvest Q3 2026 operating loss more than triples year over year to USD 3 million

BHST•2026-11-12

BioHarvest Sciences’ Q3 net loss widened 32% year over year to USD 3.3 million, while revenue fell 13% to USD 7.9 million. The company expects 2026 revenue of USD 32 million to USD 33.5 million.

1. Quarterly results and outlook

BioHarvest Sciences reported a Q3 2026 net loss of USD 3.3 million, up 32% year over year, and revenue of USD 7.9 million, down 13%. It attributed the revenue decline to moderated customer acquisition and the timing of CDMO development revenue. Management said it is prioritizing cash preservation, controlled VINIA growth and CDMO programs with near-term manufacturing potential. Limited production under a fragrance supply agreement could begin in Q1 2027, with anticipated revenue of USD 20 million to USD 30 million in 2027–2028; full-year 2026 revenue is expected to be USD 32 million to USD 33.5 million.

BioHarvest Q3 2026 operating loss more than triples year over year to USD 3 million

1. Quarterly results and outlook

Related News

Fiverr report finds 75% of US employees likely to go freelance within three years

GP-Act III seeks shareholder approval to extend business combination deadline to May 8, 2027

Belite Bio Q3 net loss widens 40% to $30.3 million

Union Pacific turns fuel surcharges into profits as rivals lag

Stifel cuts Nvidia target price to $205 from $315